Amniocentesis miscarriage risk and timing

What does the evidence say about amniocentesis during pregnancy?

1. ACOG describes amniocentesis as an ultrasound-guided procedure usually performed between 15 and 20 weeks. It can assess selected chromosome or genetic conditions, but a negative result applies only to what was tested and cannot rule out every condition. 1
2. ACOG estimates miscarriage after amniocentesis at about 1 in 900 procedures. This patient-counseling estimate includes the difficulty of separating a procedure effect from the pregnancy's background loss risk. 1
3. An updated meta-analysis of 12 controlled studies found total loss rates of 0.91% after amniocentesis and 0.58% in controls, an attributable difference of 0.30%. In studies with similar baseline-risk groups, the difference was 0.12% and its confidence interval included no increase. 2
4. MedlinePlus distinguishes amniocentesis from screening and says results depend on the analyses ordered. It advises contacting the clinician for ongoing bleeding, continuing amniotic-fluid leakage, severe cramping, or fever after the procedure. 3
5. An NCBI clinical review reports that operator experience, gestational age, multiple pregnancy, and underlying indication affect risk estimates. It also notes that Rh-negative patients may need anti-D immune globulin after the procedure, based on sensitization risk and local protocol. 4

Is amniocentesis safe in each trimester?

• First trimester. Standard amniocentesis is generally not performed before 15 weeks. If earlier diagnostic information matters, ask how chorionic villus sampling at 10 to 13 weeks differs in timing, test scope, and procedure risk.
• Second trimester. Most genetic amniocentesis occurs from 15 to 20 weeks under ultrasound guidance. Confirm exactly which laboratory analyses are ordered, how long results may take, and what findings would or would not change decisions.
• Third trimester. Later amniocentesis may be used for selected questions such as fetal infection or anemia rather than routine chromosome testing. The indication, baseline pregnancy risks, and postprocedure observation plan differ from a midtrimester procedure.